Diabetic Kidney Disease Clinical Trial
Official title:
Impact of Long-term Serum Magnesium and Potassium Levels Optimization and Multifactorial Adherence Intervention on the Progression of Diabetic Kidney Disease.
Insufficient clinical evidence correlates the progression of diabetic kidney disease with electrolyte homeostasis in patients diagnosed with type 2 diabetes mellitus (T2DM), especially in the United Arab Emirates (UAE) population and what are the most effective interventions to slow chronic renal failure progression. In our research, we test the hypothesis that low serum magnesium and potassium levels are directly associated with the decline of kidney function in diabetic patients who did not have severely impaired renal function at baseline. In addition, we describe the effect of long-term multifactorial adherence interventions on medication adherence, diet adherence and follow-up visits using a telemedicine approach such as mobile applications in reducing the progression of chronic kidney disease and other diabetes-related complications. This study is a single-blind randomized control trial to demonstrate the causal relationship between potassium and magnesium levels and estimated glomerular filtration rate (eGFR) decline. The intervention group will be evaluated for manifestations of electrolyte imbalance and correction of serum magnesium and/or potassium levels will be initiated based on the last updated laboratory test. Moreover, they will receive education to reinforce diet and exercise changes at each follow up visit by a specialized dietitian with pharmacist-led comprehensive medication therapy management utilizing multifactorial adherence interventions to measure potential drug-drug or drug-food interactions, as well as medication and follow-up adherence through an integrated mobile application and fixed medication possession ratio (FMPR). This research is under progress, and summary of its findings will be reported. This study will suggest if additional national monitoring guidelines may be warranted. In addition, it will reduce diabetic burden, medication cost in UAE and improve patient satisfaction by reducing or delaying the progression of diabetic kidney disease in diabetic patients.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | August 1, 2022 |
Est. primary completion date | May 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 61 Years |
Eligibility | Inclusion Criteria: 1. Male or female UAE citizen patients between 30 and 60 years of age. 2. Patient has been previously diagnosed with type 2 diabetes mellitus recorded in Cerner, defined by diabetes mellitus in our diagnostic criteria 3. Previously on diabetic medication recorded in Cerner and antidiabetic therapy must be unchanged for 12 weeks prior to the study. 4. Patients with normal or mild to moderate magnesium and / or potassium serum levels, as defined in our definition. 5. Patients with normal or mild impaired renal function, defined as glomerular filtration rate more than 30 ml/min and albumin/creatinine ratio = 30 mg/mmol, for more than 3 months as baseline value (Stage G1, G2, G3a and G3b of chronic kidney disease (CKD). 6. Body Mass index less than 40 at study enrollment. Exclusion Criteria: 1. Non-UAE citizen patients or patients without full insurance coverage. 2. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell population (e.g., malaria, babesiosis, hemolytic anemia). 3. Patients with severe or symptomatic hypokalemia and/or hypomagnesemia, metabolic acidosis, or hypophosphatemia with or without proximal renal tubular acidosis and Fanconi syndrome, as defined in our definition. 4. Prolonged hypokalemia with surreptitious diuretic use, laxative abuse, eating disorders, or primary aldosteronism. 5. Stage 4 or 5 CKD patients, with severe reduction in glomerular filtration rate, kidney failure or dialysis, defined as GFR = 29 ml/min or albumin/creatinine ratio ? 30 mg/mmol as baseline value. 6. High cardiovascular risk (defined as 10-year predicted ASCVD risk =7.5% by Pooled Cohort Equation or Framingham Risk Score =20%), or cardiac surgery, or angioplasty within the last 12 months or any diabetic macrovascular complications as defined in our definition. 7. Receiving medication that may cause drug-induced acute renal failure during the observational period and may be implicated in hypomagnesemia (such as aminoglycoside antibiotics, cyclosporine, amphotericin B, cisplatin, pentamidine, and foscarnet). 8. Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN) as determined at the beginning of the study or within the last 12 months. 9. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption. 10. Medical history of cancer and/or treatment for cancer within the last 5 years, or immune compromised patients. 11. Treatment with systemic steroids or change in dosage of thyroid hormones within the last 12 months after starting the study or any other uncontrolled endocrine disorder. 12. Pre-menopausal women who are nursing or pregnant within the last 12 months. 13. Patient with communication barriers that may affect obtaining patient's adherence, receiving diet, exercise counseling or consent signing, and include: 1. Patients with severe emotional distress. 2. Patients who are unable to use mobile applications or to access the internet for any reason. |
Country | Name | City | State |
---|---|---|---|
United Arab Emirates | Oud Al Touba Diagnostic and Screening center, AHS, SEHA. | Al Ain |
Lead Sponsor | Collaborator |
---|---|
United Arab Emirates University |
United Arab Emirates,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in eGFR | Difference in eGFR based on Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) and the progression to mild albuminuria. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Primary | Serum potassium and magnesium levels | The mean variation of serum potassium and magnesium levels from baseline data. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Primary | Medication adherence | Change of medication adherence measured by the fixed medication possession ratio (FMPR) equation and confirmed by medication adherence questionnaire. Patient's medication refills will be recorded in each visit and the standard adherence threshold of 0.80 MPR will be used as upper bound for mediation adherence, with MPR= 1 means perfect adherence. While an MPR < 0.50 indicates patient non-adherence, and MPR=0 means no adherence. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Primary | Dietary adherence | Assessment will utilize the revised Summary of Diabetes Self-Care Activities (SDSCA) scale using the metric "days per week" instead of using percentages and will cover diabetes self-care activities and adherence to the prescribed supplements during the past 7 days. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Primary | Lifestyle adherence | Baseline exercise counseling by our specialized dietitian, conducted for 30 minutes at initial visit upon recruitment. Reinforcing optimal exercise level will be given at each follow up visit, with exercise post- assessment questionnaire, having 2 exercise core set questions from SDSCA scale. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Secondary | HbA1c level | The difference in HbA1c level after one year. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Secondary | Optimal electrolyte levels and metabolic panel | Percentage of patients in the intervention group achieving optimal electrolyte levels and metabolic panel at the end of follow-up period. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) | |
Secondary | Side effects or complications | Development of any side effects or complications documented in patients' file. | From date of randomization until the end of the follow-up period or date of participant exit for any cause, whichever came first, assessed up to 12 months (during the study follow-up period) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006689 -
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
|
Phase 2 | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
Not yet recruiting |
NCT06120569 -
Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients
|
N/A | |
Completed |
NCT02545049 -
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
|
Phase 3 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Active, not recruiting |
NCT06176599 -
Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis
|
N/A | |
Recruiting |
NCT03716401 -
Prognostic Imaging Biomarkers for Diabetic Kidney Disease
|
||
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Completed |
NCT01377688 -
Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes
|
N/A | |
Active, not recruiting |
NCT05514548 -
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
|
Phase 2 | |
Recruiting |
NCT05507892 -
Renal Mechanism of SGLT2 Inhibition
|
Phase 2 | |
Not yet recruiting |
NCT06049550 -
The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
|
||
Not yet recruiting |
NCT05514184 -
Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT04589351 -
Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
|
Phase 3 | |
Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
Suspended |
NCT01878045 -
Mechanisms of Diabetic Kidney Disease in American Indians
|